HCV NS5B Inhibitor Compounds for Genotype 1 Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, particularly for genotype 1, with existing treatments showing only 50% sustained virologic response and severe side effects, highlighting the need for improved antiviral drugs with better efficacy and safety profiles.
Innovation Solution
Development of novel compounds of formula I, which are effective against HCV, including pharmaceutically acceptable salts, that target specific mechanisms of action, binding, inhibition, target selectivity, solubility, safety profiles, and bioavailability, potentially inhibiting HCV NS5B protein and other viral functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (pegylated alpha-interferon and ribavirin) are used for HCV genotype 1, then treatment coverage is provided, but sustained virologic response is only achieved in approximately 50% of patients with severe side effects
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (formula I with specific substituents R1-R6, Ar1, and ring A) that change the pharmacological parameters of HCV treatment. These structural modifications aim to achieve higher potency and selectivity against HCV while reducing off-target effects that cause side effects.
Solution Approach 2:
The patent creates new chemical entities that copy and optimize the mechanism of action of existing antiviral compounds. By designing analogs with improved pharmacological properties, the invention seeks to replicate the therapeutic effect of current treatments while eliminating their limitations in efficacy and safety.
2Adaptability or versatility
If combination therapy with pegylated alpha-interferon and ribavirin is administered, then broad antiviral coverage is achieved, but treatment complexity and side effect profile increase
Solution Approach 1:
The patent develops compounds that aim to provide multi-functional antiviral activity against HCV. The chemical structure of formula I is designed to target multiple viral proteins (NS5B polymerase, NS3 protease, NS5A) with a single agent, thereby simplifying the treatment regimen while maintaining broad antiviral coverage.
Solution Approach 2:
The invention merges multiple antiviral mechanisms into a single compound molecule. By incorporating structural features that can interact with different viral targets, the patent seeks to combine the effects of multiple drugs into one agent, reducing treatment complexity.
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.